SymBio Pharmaceuticals Limited
Exclusive Global License for BCV Obtained for MS – Licensing Agreement for development with U.S. Department of Health and Human Services
Entered into an exclusive global license for BCV as a treatment and preventive for MS via NIH/NINDS. Also reports CRADA extension and development progress toward clinical trials. States no impact on consolidated results for the fiscal year ending December 2026.
Key Figures
- CRADA extension: extended by 3 years (announced March 30, 2026)
- BCV shows hints of selectively targeting EB virus–negative B cells (research findings)
- No impact on fiscal year 2026 consolidated results (stated in text)
AI要約
Section Heading
SymBio Pharmaceuticals entered into an exclusive global licensing agreement to develop Brinsidovir (BCV) as a treatment and preventive for multiple sclerosis (MS) after signing a CRADA with the U.S. NIH/NINDS in March 2023. The latest release reports that BCV inhibits EB virus at low concentrations in research findings and that the CRADA has been extended by three years. Development will continue with a view toward clinical trials. The company states there will be no impact on consolidated results for the fiscal year ending December 2026.
Section 2 Heading
This matter directly relates to a CRADA utilizing public research resources involving HHS/NINDS and the development of a new therapy using BCV. The CRADA extension ensures continued preclinical and in vivo testing, with preparations for future clinical trials under way. For investors, progress in innovative therapeutic approaches and the timeline until these efforts affect financial metrics are key points.
SymBio Pharmaceuticals Limited
Company overview · Stock price · Financial data · All IR
